Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025 ...

In the late-breaking abstract, Recursion presented preliminary data as of February 7, 2025, showing that 13 patients received 4 mg of REC-4881 QD, with 84.6% experiencing at least one treatment ...

You can reach Allison on Signal at AllisonDeAngelis.01. Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper ...

This paper presents the Seed tool that can be used for the uniform random generation of recursive data structures ... at random k structures of size n with an efficient time complexity. Finally, Seed ...

While Recursion is probably the best positioned AI drug discovery company, the stock could pull back if AI hype fades. Recursion could benefit from a series of clinical data in coming quarters though.

Recursion, a biopharma company, uses a data-driven approach to drug discovery ... which could significantly reduce the time it takes to run a SAR (Structure-Activity Relationship) cycle.

We discuss how to work with directories, sub-directories, and traverse them using Java and the DirectoryStream method. Learn more. A directory is an organizational file system structure that ...